Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
SI-BONE is a medical device company that has pioneered a proprietary minimally inv...
SI-BONE is a medical device company that has pi...
Although intended for the lungs, many drugs are not given via the airway because d...
Although intended for the lungs, many drugs are...
Novanta is a leading global supplier of core technology solutions that give medica...
Novanta is a leading global supplier of core te...
ArQule is a biopharmaceutical company engaged in the research and development of t...
ArQule is a biopharmaceutical company engaged i...
Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on...
Outlook Therapeutics is a late clinical-stage b...
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on...
Deciphera Pharmaceuticals is a clinical-stage b...
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on deve...
Aptevo Therapeutics Inc. is a clinical-stage bi...
Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...
Vaccinex is a clinical-stage biotechnology comp...
Join the National Investor Network and get the latest information with your interests in mind.